Trials / Completed
CompletedNCT04848402
A Device Study in Healthy Participants
A Study to Investigate the Safety and Tolerability of a Wearable On-body Delivery System, and Exploratory Assessment of Participant Response With an Autoinjector, Following Subcutaneous Injections of Placebo in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to evaluate the safety and tolerability of two different devices that may be used to inject medication just under the skin. Participants will receive placebo; no active drug will be given. The study will last up to five weeks for each participant, including a one-week overnight stay in the study center.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | On-Body Delivery System (OBDS)/Multiple Bolus Injector | Used to administer placebo SC. |
| DEVICE | Single Auto Injector | Used to administer placebo SC. |
| DRUG | Placebo | Administered SC. |
Timeline
- Start date
- 2021-09-27
- Primary completion
- 2022-07-22
- Completion
- 2022-07-22
- First posted
- 2021-04-19
- Last updated
- 2023-03-01
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04848402. Inclusion in this directory is not an endorsement.